Breast surgery for low-grade ductal carcinoma may not improve survival
the ONA take:
According to a new study published in JAMA Surgery, researchers from Brigham and Women's Hospital in Boston, Massachusetts, have found that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ (DCIS) experienced no difference in survival compared with those who did not receive surgery.
For the retrospective analysis, researchers analyzed data from over 50,000 cases of DCIS available from the Surveillance, Epidemiology and End Results (SEER) database between 1998 and 2011. All patients were treated at Dana-Farber/Brigham and Women's Cancer Center.
Results showed that patients with low-grade DCIS who did not receive surgery at or shortly after diagnosis had a 10-year survival rate of 98.8% compared with 98.6% for those who did receive surgery; however, women with intermediate- or high-grade DCIS, the survival rate was significantly higher for those who had surgery versus those who did not.
The researchers note that a prospective clinical trial is warranted before it can be concluded that breast surgery should be avoided for women with low-grade DCIS.
Breast surgery performed at or shortly after a diagnosis of low-grade ductal carcinoma in-situ experienced no difference in survival.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|